Floatz logo

Retigabine

Anhedonia

James MurroughSmall moleculePhase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Anhedonia cohort.

Asset / SponsorPhaseRating
DESVENLAFAXINE
Jiangsu Province Nanjing Brain Hospital
Phase 4BB
17-beta-estradiol
University of North Carolina, Chapel Hill
Phase 4BB
(S)-3,5-DICHLORO-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)-6-HYDROXY-O-ANISAMIDE
University of North Carolina, Chapel Hill
Phase 4BB
Prometrium
University of North Carolina, Chapel Hill
Phase 4BB
TEONANACATL
Medical University of Vienna
Phase 2BB

View all 16 →

Same molecule, other indications

Retigabine is also rated in:

epilepsyDormant
BB
Indicative ·
69 / 100
View asset →
epilepsyDormant
BB
Indicative ·
67 / 100
View asset →
childhood-onset epilepsy syndromeDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →